18555-63-0Relevant academic research and scientific papers
PRMT5 INHIBITORS
-
Page/Page column 120-121, (2020/03/02)
The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
Cyclic dinucleotide compound, preparation method and application thereof
-
Paragraph 0378-0380, (2019/05/11)
The invention discloses a cyclic dinucleotide compound, a preparation method and an application thereof, specifically, the invention relates to a compound of a formula (I), a pharmaceutically acceptable salt thereof, the preparation method thereof, and the application in the preparation of a medicine for treatment and/or prevention of a disease associated with activation of STING protein or as a vaccine adjuvant. The diseases associated with activation of the STING protein include viral infections, bacterial infections, cancers, diseases related to the immune system, and the like.
CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING
-
Paragraph 0279; 0280, (2018/09/26)
Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.
CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE
-
Paragraph 0219, (2017/10/11)
Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.
2',3'-O-Silylation of Tubercidin with tert-Butyl(chloro)dimethylsilane
Seela, Frank,Hissmann, Edith,Ott, Johann
, p. 1169 - 1176 (2007/10/02)
Silylation of tubercidin (1a) with an excess of tert-butyl(chloro)dimethylsilane gives the 2',3',5'-tri-O-silyl derivative 1b.On the same route compound 2b was formed from N4-benzoyltubercidin.Formation of the disilyl derivative 1c or 2c has be
